[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201591049A1 - Способы получения конъюгатов дисульфидсодержащих белков - Google Patents

Способы получения конъюгатов дисульфидсодержащих белков

Info

Publication number
EA201591049A1
EA201591049A1 EA201591049A EA201591049A EA201591049A1 EA 201591049 A1 EA201591049 A1 EA 201591049A1 EA 201591049 A EA201591049 A EA 201591049A EA 201591049 A EA201591049 A EA 201591049A EA 201591049 A1 EA201591049 A1 EA 201591049A1
Authority
EA
Eurasian Patent Office
Prior art keywords
protein
cysteine residues
sulfur atoms
methods
payload
Prior art date
Application number
EA201591049A
Other languages
English (en)
Inventor
Ци-Ин Ху
Хидетомо Имасе
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201591049A1 publication Critical patent/EA201591049A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
    • A61F5/0003—Apparatus for the treatment of obesity; Anti-eating devices
    • A61F5/0006—Diet or mouth appliances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
    • A61C5/00—Filling or capping teeth
    • A61C5/90—Oral protectors for use during treatment, e.g. lip or mouth protectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
    • A61F5/56—Devices for preventing snoring
    • A61F5/566—Intra-oral devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nursing (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Dentistry (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)

Abstract

Настоящее изобретение относится к способам получения конъюгатов белков, содержащих по меньшей мере два цистеина. В одном варианте осуществления белок, содержащий дисульфидную связь, восстанавливают с получением двух свободных цистеиновых остатков с их последующим взаимодействием с 1,3-дигалогенацетоном или подобным реагентом, соединяющим вместе атомы серы двух цистеиновых остатков. Кетон, вставленный между атомами серы, затем используют для получения шиффова основания с аминированной молекулой полезной нагрузки и, таким образом, конъюгирования белка с полезной нагрузкой. В другом варианте осуществления два цистеиновых остатка соединяют путем взаимодействия с 1,3-дигалогенацетоном или подобным реагентом. Связь между атомами серы, в каждом случае, поддерживает белок или пептид в напряженной конформации, предоставляя, таким образом, удобный участок для присоединения полезной нагрузки с хорошей специфичностью и эффективностью.
EA201591049A 2012-11-30 2013-11-26 Способы получения конъюгатов дисульфидсодержащих белков EA201591049A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261731852P 2012-11-30 2012-11-30
PCT/IB2013/060427 WO2014083505A1 (en) 2012-11-30 2013-11-26 Methods for making conjugates from disulfide-containing proteins

Publications (1)

Publication Number Publication Date
EA201591049A1 true EA201591049A1 (ru) 2015-09-30

Family

ID=49726841

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591049A EA201591049A1 (ru) 2012-11-30 2013-11-26 Способы получения конъюгатов дисульфидсодержащих белков

Country Status (13)

Country Link
US (3) US10022256B2 (ru)
EP (1) EP2925368B1 (ru)
JP (1) JP6408480B2 (ru)
KR (1) KR20150090081A (ru)
CN (1) CN104853781B (ru)
AU (1) AU2013350802B2 (ru)
BR (1) BR112015011317A2 (ru)
CA (1) CA2888445A1 (ru)
EA (1) EA201591049A1 (ru)
ES (1) ES2732574T3 (ru)
IN (1) IN2015DN02913A (ru)
MX (1) MX2015006868A (ru)
WO (1) WO2014083505A1 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201591049A1 (ru) 2012-11-30 2015-09-30 Новартис Аг Способы получения конъюгатов дисульфидсодержащих белков
MX2016001020A (es) * 2013-07-25 2016-08-03 Novartis Ag Polipeptidos ciclicos para el tratamiento de insuficiencia cardiaca.
US9683018B2 (en) 2013-07-25 2017-06-20 Novartis Ag Disulfide cyclic polypeptides for the treatment of heart failure
US9908919B2 (en) 2013-07-25 2018-03-06 Novartis Ag Cyclic apelin derivatives for the treatment of heart failure
US9340582B2 (en) * 2013-07-25 2016-05-17 Novartis Ag Bioconjugates of synthetic apelin polypeptides
WO2015079376A1 (en) 2013-11-26 2015-06-04 Novartis Ag Methods for oxime conjugation to ketone-modified polypeptides
US20150182373A1 (en) * 2014-01-02 2015-07-02 DMD Todd D. Morgan Oral Exercise Appliance
ES2792598T3 (es) 2014-05-23 2020-11-11 Novartis Ag Métodos para preparar conjugados a partir de proteínas que contienen disulfuro
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3310813A1 (en) 2015-06-17 2018-04-25 Novartis AG Antibody drug conjugates
EP3310373A4 (en) 2015-06-22 2019-02-13 University of Utah Research Foundation STAPLING THIOL-EENE-BASED PEPTIDES AND USES THEREOF
MA44334A (fr) * 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
WO2017219025A1 (en) * 2016-06-17 2017-12-21 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cells
US11034720B2 (en) 2016-07-17 2021-06-15 University Of Utah Research Foundation Thiol-yne based peptide stapling and uses thereof
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
WO2020089815A1 (en) 2018-10-31 2020-05-07 Novartis Ag Antibody conjugates comprising sting agonist
US11486864B2 (en) * 2019-01-16 2022-11-01 Regeneron Pharmaceuticals, Inc. Method and system of identifying and quantifying antibody fragmentation
US20230092679A1 (en) 2019-05-20 2023-03-23 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
US20230091510A1 (en) 2019-05-20 2023-03-23 Novartis Ag Antibody drug conjugates having linkers comprising hydrophilic groups
AU2021373429A1 (en) * 2020-11-09 2023-06-15 Kagoshima University Peptide crosslinking agent and crosslinked peptide which is crosslinked using said crosslinking agent
WO2023201181A2 (en) * 2022-04-15 2023-10-19 Jeffrey Goldberg Hunger satiating dental appliance
WO2024189481A1 (en) 2023-03-10 2024-09-19 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239110B1 (en) 1990-02-22 2001-05-29 W.R. Grace & Co. -Conn. Synthetic analogs of thrombospondin and therapeutic use thereof
WO1999013062A1 (en) 1997-09-09 1999-03-18 Nycomed Imaging As Factors vii fragments and analogs thereof and their use in the treatment of blood clotting disorders
WO1999013063A1 (en) 1997-09-09 1999-03-18 Nycomed Imaging As Factor vii fragments and analogs thereof and their use in the treatment of blood clottng disorders
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
CN101400646A (zh) * 2005-11-08 2009-04-01 Ambrx公司 用于修饰非天然氨基酸和非天然氨基酸多肽的促进剂
US20090131306A1 (en) 2007-06-15 2009-05-21 Adherex Technologies, Inc. Chemically modified cyclic peptides containing cell adhesion recognition (car) sequences and uses therefor
PL2257624T3 (pl) 2008-02-05 2012-09-28 Medical Res Council Sposoby i kompozycje
AU2009290137A1 (en) 2008-09-03 2010-03-11 Xenome Ltd Libraries of peptide conjugates and methods for making them
EP2889624B1 (en) 2009-08-10 2018-10-03 UCL Business PLC Reversible covalent linkage of functional molecules
US20150231240A1 (en) 2012-10-09 2015-08-20 Igenica Biotherapeutics, Inc. Anti-c16orf54 antibodies and methods of use thereof
US9428589B2 (en) 2012-11-15 2016-08-30 Brandeis University Tethering cysteine residues using cyclic disulfides
EA201591049A1 (ru) 2012-11-30 2015-09-30 Новартис Аг Способы получения конъюгатов дисульфидсодержащих белков
WO2015079376A1 (en) 2013-11-26 2015-06-04 Novartis Ag Methods for oxime conjugation to ketone-modified polypeptides

Also Published As

Publication number Publication date
US10022256B2 (en) 2018-07-17
MX2015006868A (es) 2015-10-05
JP2015537045A (ja) 2015-12-24
CN104853781A (zh) 2015-08-19
EP2925368A1 (en) 2015-10-07
EP2925368B1 (en) 2019-03-27
JP6408480B2 (ja) 2018-10-17
KR20150090081A (ko) 2015-08-05
CN104853781B (zh) 2017-10-24
WO2014083505A1 (en) 2014-06-05
AU2013350802A1 (en) 2015-04-09
CA2888445A1 (en) 2014-06-05
US11311400B2 (en) 2022-04-26
AU2013350802B2 (en) 2016-07-14
US20200253768A1 (en) 2020-08-13
BR112015011317A2 (pt) 2017-07-11
US20190038444A1 (en) 2019-02-07
ES2732574T3 (es) 2019-11-25
US10667935B2 (en) 2020-06-02
IN2015DN02913A (ru) 2015-09-18
US20150290009A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
EA201591049A1 (ru) Способы получения конъюгатов дисульфидсодержащих белков
CY1123618T1 (el) Πολυπεπτιδια αντισωματα που ανταγωνιζονται cd40l
EA201691075A1 (ru) Способы оксимной конъюгации с кетон-модифицированными полипептидами
CY1122691T1 (el) Πρωτεϊνες δεσμευσης αλβουμινης ορου
CY1120637T1 (el) Πολυπεπτιδικα αντισωματα που ανταγωνιζονται cd40
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
GT200600186A (es) Agentes de unión
CY1120398T1 (el) Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
MX2018008680A (es) Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43).
CL2013001279A1 (es) Anticuerpo humano aislado o fragmento de union a antigeno del mismo que se une especificamente y neutraliza la actividad del ligando 1a de tipo tnf humano (htl1a); molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso.
CL2013003090A1 (es) Polipeptido que comprende una primera secuencia de aminoacidos que comprende a su vez al menos un dominio variable individual de inmunoglobulina que se enlaza especificamente a il-17f, il17-a/f, pero no a il-17a, y una segunda secuencia de aminoacidos que comprende a su vez al menos un dominio variable individual de inmunoglobulina que se enlaza especificamente a il-17a, il-17f y il17-a/f; composicion farmaceutica que lo comprende; y su uso.
CY1117563T1 (el) Αντισωματα κατα her3 και χρησεις αυτων
CY1118014T1 (el) Aνti-il-23 αντισωματα
TR201910213T4 (tr) Disülfürle stabilize edilmiş çok değerlikli antikorlar.
CO6280541A2 (es) Anticuerpos monoclonales o fragmentos del mismo que se unen al recptor humano ox40
WO2013054331A8 (en) Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
EA201490677A1 (ru) Связывающие антиген cd27l белки
EA201391753A1 (ru) Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке
MX2009006199A (es) Formulacion parenteral de anticuerpos abeta.
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
NZ701040A (en) Covalently linked antigen-antibody conjugates
BR112013023006A8 (pt) formulações de suspensões não aquosas de anticorpos de alta concentração e viscosidade reduzida
BRPI0607323B8 (pt) composições, usos de polipeptídeos e de anticorpos, bem como kits para a detecção de anticorpo que se liga especificamente a um polipeptídeo